Biote Corp
Company Profile
Business description
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company provides support to medical practitioners through training, practice development, and operational services to establish and manage hormone therapy centers. Its activities include educating practitioners on identifying and treating hormone-related conditions. The company generates revenues by charging the Biote-partnered clinics fees associated with the Biote Method and from the sale of Biote-branded dietary supplements.
Contact
1875 W. Walnut Hill Lane
Suite 100
IrvingTX75038
USAT: +1 844 604-1246
Sector
Healthcare
Stock type
Defensive
Industry
Medical Care Facilities
Fiscal Year End
31 December 2026
Employees
223
Stocks News & Analysis
stocks
Chart of the Week: BHP’s growth story faces a reality check
stocks
3 best ASX growth stocks to buy for the long term
stocks
The ASX data center stock flying under the radar
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,036.90 | 13.00 | -0.14% |
| CAC 40 | 8,377.86 | 4.57 | -0.05% |
| DAX 40 | 24,915.49 | 84.04 | -0.34% |
| Dow JONES (US) | 52,552.97 | 105.67 | -0.20% |
| FTSE 100 | 10,572.24 | 56.32 | 0.54% |
| HKSE | 25,008.60 | 327.50 | 1.33% |
| NASDAQ | 25,881.95 | 387.28 | -1.47% |
| Nikkei 225 | 66,835.54 | 1,915.97 | -2.79% |
| NZX 50 Index | 13,614.78 | 20.29 | -0.15% |
| S&P 500 | 7,533.77 | 38.63 | -0.51% |
| S&P/ASX 200 | 8,840.70 | 15.50 | -0.18% |
| SSE Composite Index | 3,882.41 | 73.17 | -1.85% |